Chiesi the Netherlands was established in 2007. We have since grown to become a reputable player in the Dutch pharmaceutical industry.
This evolution is driven by three key factors: the introduction of innovative medicines from our own pipeline
, the development of existing medicines, and a successful acquisition and licensing strategy. Chiesi the Netherlands has an extensive product portfolio and focuses on six areas: asthma, COPD, CF, neonatology, transplantation and rare diseases. Our entrepreneurial and flexible approach is a key success factor for Chiesi the Netherlands, and is highly valued by our customers.